c-MET Signaling Reshapes the Lung Cancer Immune Landscape in Space and Metabolism

Lung cancer remains one of the most formidable challenges in modern oncology, and despite decades of progress in targeted therapy and immunotherapy, many patients still develop resistance to the treatments designed to save them. A newly published review in the Journal of Translational Medicine argues that part of the answer may lie in a signaling pathway that oncologists have long studied for its direct effects on tumor cells but have only recently begun to appreciate for its influence on the immune system itself. The review, authored by Danxue Zhu and Sitian Zang, examines the hepatocyte growth factor receptor known as c-MET and proposes that this oncogenic driver does far more than fuel tumor growth. According to the authors, MET activity appears to sculpt the tumor microenvironment, linking the intrinsic wiring of cancer cells to immune suppression and metabolic reprogramming in ways that vary dramatically from one region of a tumor to another.

The HGF/c-MET axis has long been recognized as a central oncogenic driver in lung cancer. When hepatocyte growth factor binds to the MET receptor tyrosine kinase, it triggers intracellular cascades that promote tumor cell proliferation, epithelial-to-mesenchymal transition, invasion, and metastasis. Aberrant MET activation, whether through gene amplification, exon 14 skipping mutations, or autocrine ligand production, is a well-documented mechanism of resistance to EGFR-targeted therapies in non-small cell lung cancer. MET inhibitors have been developed and approved for subsets of patients whose tumors harbor specific MET alterations, and these drugs can produce striking responses. Yet the review emphasizes that clinical outcomes have been inconsistent, and the authors contend that a purely gene-centric view of MET targeting fails to capture the full biological complexity of MET dependency in tumors.

The core argument of the review is that MET signaling operates within a spatially heterogeneous and dynamically regulated context. MET activity is not uniform across a tumor; instead, it varies from region to region, shaped by local metabolic states, interactions with stromal cells, and the co-activation of other oncogenic pathways. This spatial heterogeneity means that a biopsy taken from one part of a tumor may not reflect the signaling landscape elsewhere, and a treatment decision based on static genomic alterations alone may miss functionally important MET-driven states. The authors argue that emerging technologies, including spatial transcriptomics, single-cell profiling, and integrative metabolic assessments, are revealing that MET dependency is a multidimensional property that cannot be reduced to the presence or absence of a genomic alteration on a pathology report.

One of the most compelling aspects of the review is its synthesis of how MET signaling may contribute to the formation of localized immunosuppressive niches within tumors. The authors describe several converging mechanisms. MET activity appears to modulate glycolytic reprogramming, the metabolic shift by which cancer cells preferentially consume glucose and produce lactate even in the presence of oxygen. Lactate accumulation in the tumor microenvironment is well known to impair the function of cytotoxic T lymphocytes and natural killer cells, the immune cells responsible for killing tumor cells. By promoting lactate production, MET-driven tumors may create acidic microenvironments that exclude or disable the very immune cells that immunotherapies rely upon.

Beyond lactate, the review highlights adenosine signaling as another metabolic route through which MET may foster immune evasion. Adenosine accumulates in hypoxic and metabolically stressed tumor regions and, through its receptors on immune cells, exerts potent immunosuppressive effects, dampening T cell activity and promoting the expansion of regulatory immune populations. The authors suggest that MET signaling intersects with these purinergic metabolic pathways, potentially amplifying the immunosuppressive tone of the microenvironment in a spatially confined manner. In parallel, MET activity appears to influence the expression of immune checkpoint molecules such as PD-L1, the molecular brakes that tumors use to evade T cell attack. If MET signaling upregulates checkpoint expression in specific tumor niches, it could explain why immune checkpoint blockade, one of the great success stories of modern lung cancer treatment, fails in some patients despite apparently favorable biomarkers.

The review also draws attention to cancer-associated fibroblasts, or CAFs, as key architectural partners in MET-driven immune exclusion. These stromal cells are increasingly recognized as active participants in tumor progression, secreting growth factors, remodeling the extracellular matrix, and physically organizing the tumor into functional microdomains. The authors propose that MET signaling and CAF-mediated interactions cooperate to create localized pockets of immune suppression, where excluded T cells accumulate at the tumor periphery while the tumor core remains immunologically silent. This spatial organization has profound therapeutic implications, because a drug that works beautifully in one region of a tumor may be irrelevant in another where different signaling and metabolic conditions prevail.

What makes this synthesis particularly timely is the convergence of new profiling technologies that make such context-aware analysis feasible. Spatial transcriptomics allows researchers to map gene expression across intact tissue sections, preserving the architectural information that conventional bulk sequencing destroys. Single-cell RNA sequencing resolves the diversity of individual cells within a tumor, distinguishing malignant subclones, immune subsets, and stromal populations that would otherwise be averaged together. Integrative metabolic assessments add yet another layer, connecting gene expression to the biochemical states that govern immune cell function. Applied together, these tools can identify biologically coherent MET-driven tumor states, defined not just by genomic alterations but by the spatial, metabolic, and immune features that determine how a tumor actually behaves in a patient.

The therapeutic implications of this reframing are substantial. The authors argue that the field should move beyond a purely gene-centric view of MET targeting toward context-aware strategies. In practice, this could mean combining MET inhibitors with immunomodulatory agents, such as immune checkpoint blockers, to address the immune suppression that MET signaling helps establish. It could also mean pairing MET inhibition with metabolic interventions designed to counteract the glycolytic and adenosine-mediated mechanisms that create immunologically cold tumor niches. The logic is that targeting MET alone may dismantle one pillar of tumor fitness while leaving the spatially confined immune and metabolic defenses intact, whereas rational combinations could overcome resistance mechanisms that emerge from the microenvironment rather than from the cancer cell itself.

For patients with MET-driven lung cancer, the promise of such combination strategies is tempered by the challenges that always accompany biomarker-driven medicine. Defining which patients will benefit from MET inhibition, predicting who will respond to immunotherapy, and identifying the right combinations for the right tumor states all require biomarker frameworks far more sophisticated than those in current clinical use. The review’s proposal for multidimensional biomarkers that incorporate spatial, metabolic, and immune parameters represents an ambitious step in that direction. If validated, such frameworks could transform how oncologists select therapies, replacing single-gene tests with integrated profiles that capture the biological reality of each patient’s tumor. The path from this conceptual synthesis to clinical practice will require prospective studies, but the direction is clear: the future of MET-targeted therapy in lung cancer may depend less on the mutation a tumor carries and more on the landscape it creates around itself.

Subject of Research: The role of c-MET signaling in shaping the spatial and metabolic immune landscape of lung cancer

Article Title: Reprogramming the immune landscape in lung cancer: spatial and metabolic contexts of c-MET signaling

Article References: Zhu, D., & Zang, S. (2026). Reprogramming the immune landscape in lung cancer: spatial and metabolic contexts of c-MET signaling. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08900-w

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08900-w

Keywords: c-MET signaling, HGF, lung cancer, NSCLC, tumor microenvironment, immunometabolism, spatial transcriptomics, immune checkpoint blockade, cancer-associated fibroblasts, glycolytic reprogramming, lactate, targeted therapy